Mitsui Fudosan and Axil Capital have established Mitsui Link-Fund, a new corporate venture capital fund with a total size of 7 billion yen. The fund was announced in Tokyo on August 31, 2026, and will invest in life science start-ups from research seed commercialization through later-stage growth. Its creation is intended to strengthen the life science ecosystem by adding a dedicated direct investment vehicle to existing support programs.
Fund Focus and Investment Strategy
The new fund will focus primarily on drug discovery, medical devices, regenerative medicine, and healthcare and health tech. It will invest in start-ups that offer innovative technologies and services and are expected to help solve societal issues or contribute to the creation of new industries. Because research and development in life science requires long timelines and substantial capital at each growth stage, the fund will provide support from seed through late-stage financing rounds.
Operational Leadership and Scientific Guidance
Axil Capital, an independent venture capital firm with a strong investment record in life science, will operate the fund. RealizeEdge Partners will serve as a scientific collaborator, contributing extensive expertise in drug discovery research and development. Their combined knowledge in scientific evaluation and commercialization support is designed to help start-ups progress at various stages of growth.
Existing Infrastructure and Community Networks
Mitsui Fudosan launched its life science innovation promotion project in 2016 and has since built a broad support infrastructure. This includes research and development sites such as the Nihonbashi Life Science Building series and the MITSUI LINK-Lab rental laboratory and office business. It has also developed community networks through LINK-J and provided capital through limited partner investments in venture capital funds.
Ecosystem Integration and Long-Term Vision
LINK-J now has 1,041 special members as of February 2026 and has hosted more than 7,000 events and programs over the past ten years. The platform connects industry, universities, government, start-ups, venture capital firms, and support organizations to promote interaction and co-creation. Mitsui Link-Fund is intended to integrate with this network under Mitsui Fudosan's long-term vision, AND INNOVATION 2030, linking sites, communities, and funds.
Capital Support Across Development Stages
The fund goes beyond financial support provided through traditional limited partner investments by strengthening direct growth capital for life science start-ups. It enables Mitsui Fudosan to work with the Axil Capital Group, which invests broadly in life science venture firms from early stages through crossover financing rounds in late stages. This structure supports companies that require repeated funding over long research and development cycles.
A Total Support Framework
The establishment of Mitsui Link-Fund completes a framework that unites physical sites, community networks, and funding within one coordinated initiative. Mitsui Fudosan has expanded the Nihonbashi Life Science Building series and developed rental laboratory and office facilities where start-ups, pharmaceutical companies, universities, research institutions, venture capital firms, and support organizations can cluster. The new fund adds continuous capital provision to this environment, helping research outcomes move toward practical use.
By combining Axil Capital's investment knowledge, RealizeEdge Partners' commercialization expertise, and Mitsui Fudosan's sites and business platforms, the initiative provides total support from research seed commercialization through growth and implementation in society. The new fund is expected to accelerate open innovation and contribute to the creation of new industries in the life science field. It represents a coordinated effort to strengthen Japan's life science ecosystem and address long-standing societal challenges.